SCHEMBL4303343

SCHEMBL4303343

CN(C)c1ccc(C(N)=S)c(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.42
MAPT P10636 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
GAA P10253 2/20 0.42
KMT2A Q03164 1/20 0.42
AVPR2 P30518 2/20 0.39
FLT1 P17948 1/20 0.38
FLT4 P35916 1/20 0.38
KDR P35968 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
MCL1 Q07820 1/20 0.37
ADRA2A P08913 2/20 0.36
ADRA2B P18089 2/20 0.36
ADRA2C P18825 2/20 0.36
MAPK13 O15264 1/20 0.36
MAPK12 P53778 1/20 0.36
MAPK11 Q15759 1/20 0.36
MAPK14 Q16539 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4301391 0.79 ALDH1A1 (0.43) ALDH1A1MAPTSMN1; SMN2GAAKMT2A
SCHEMBL4306068 0.78 ALDH1A1 (0.42) ALDH1A1MAPTSMN1; SMN2GAAKMT2A
SCHEMBL4302622 0.78 ALDH1A1 (0.42) ALDH1A1MAPTSMN1; SMN2GAAKMT2A
SCHEMBL17142873 0.76 SMN1; SMN2 (0.57) ALDH1A1MAPTSMN1; SMN2KMT2AAVPR2
SCHEMBL27680097 0.76 AVPR2 (0.46) ALDH1A1MAPTSMN1; SMN2KMT2AAVPR2
SCHEMBL4302585 0.75 PSMB5 (0.41) ALDH1A1MAPTSMN1; SMN2GAAKMT2A
SCHEMBL4301042 0.75 ALDH1A1 (0.67) ALDH1A1MAPTSMN1; SMN2GAAKMT2A
SCHEMBL6897299 0.75 RAB9A (0.47) ALDH1A1MAPTSMN1; SMN2GAAKMT2A
SCHEMBL20077098 0.74 ALDH1A1 (0.50) ALDH1A1MAPTSMN1; SMN2KMT2AAVPR2
SCHEMBL2026918 0.74 TSHR (0.54) ALDH1A1MAPTSMN1; SMN2GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270363-A1 2-Aryl- and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof WYETH (US) 2009-10-29 US disclosed
US-20090270363-A1 2-Aryl- and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof WYETH (US) 2009-10-29 US disclosed
US-20090270363-A1 2-Aryl- and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof WYETH (US) 2009-10-29 US disclosed
WO-2009120826-A1 2-ARYL- AND 2-HETEROARYLTHIAZOLYL COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF WYETH (US) 2009-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270363-A1 2-Aryl- and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof SEC63, SEC62, SEC22B ALDH1A1 2705/4885MAPT 2418/4885SMN1; SMN2 2004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.